A final line has been drawn under cadazolid as an initially promising but ultimately disappointing treatment for the management of C. difficile infections. The IMPACT 1 and 2 trials of the novel quinoxolidinone antibiotic versus vancomycin, published together in The Lancet Infectious Diseases, failed to show overall superiority of cadazolid over vancomycin. “Further commercial development ...
New antibiotics needed for C. difficile as promising drug abandoned
By Mardi Chapman
7 Feb 2019